1. A systematic review and meta-analysis of traditional Chinese medicine with chemotherapy in breast cancer
- Author
-
Juan Wu, Dan Yu, Ruizhen Huang, Yanru Liu, Cheng Shun Zhang, and Gang Shi
- Subjects
Oncology ,0303 health sciences ,medicine.medical_specialty ,Chemotherapy ,Performance status ,business.industry ,medicine.medical_treatment ,Odds ratio ,Traditional Chinese medicine ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,030220 oncology & carcinogenesis ,Internal medicine ,Meta-analysis ,medicine ,Hemotherapy ,Surgery ,Original Article ,business ,Neoadjuvant therapy ,030304 developmental biology - Abstract
BACKGROUND: With the continuous progression of a new generation of adjuvant chemotherapy, the survival time of breast cancer patients has also been significantly improved. Chemotherapy alone will cause a series of side effects, which will seriously affect the quality of life of breast cancer patients. Chinese medicine combined with neoadjuvant chemotherapy has a unique advantage in the treatment of breast cancer. METHODS: English databases were searched using combinations of the following search terms: “traditional Chinese medicine”, “neoadjuvant hemotherapy”, “breast cancer”, and “tumor of breast”. Publications in which traditional Chinese medicine (TCM) combined with neoadjuvant therapy was the experimental group and chemotherapy alone was the control group were screened. RESULTS: A total of 12 publications were included in the meta-analysis. The efficiency of the performance status score was used to test for heterogeneity, Chi(2)=2.95, df=5, P=0.71>0.1, I(2)=0%, Z=3.36, odds ratio (OR) =2.61, and 95% confidence interval (CI), 1.49–4.58. The results of the heterogeneity test of the effective rate of the objective curative effect were as follows: Chi(2)=1.04, df=7, P=0.99>0.1, I(2)=0%0.1, I(2)=0%
- Published
- 2021